![Matt Hall](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matt Hall
Contatto Relazioni con gli Investitori presso
ANIKA THERAPEUTICS, INC.
Profilo
Matt Hall currently works at Diagnotes, Inc., as Director, Anika Therapeutics, Inc., as Director-Development & Investor Relations from 2024, The Central Indiana Corporate Partnership, as Senior Vice President from 2004, and Allinaire Therapeutics LLC, as Board Member from 2016.
Mr. Hall also formerly worked at BioCrossroads, as Managing Director from 2017 to 2022 and NatCity Investments, Inc., as Vice President.
Mr. Hall received his graduate degree in 1991 from Butler University and undergraduate degree from Indiana University.
Posizioni attive di Matt Hall
| Società | Posizione | Inizio |
|---|---|---|
| ANIKA THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | 01/09/2024 |
Diagnotes, Inc.
 Diagnotes, Inc. Packaged SoftwareTechnology Services Provides a communication platform for on-call healthcare services | Direttore/Membro del Consiglio | - |
Allinaire Therapeutics LLC
 Allinaire Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for cardiopulmonary diseases | Direttore/Membro del Consiglio | 01/01/2016 |
The Central Indiana Corporate Partnership
 The Central Indiana Corporate Partnership Miscellaneous Commercial ServicesCommercial Services Engages in focusing on human capital, entrepreneurship and innovation & business climate | Corporate Officer/Principal | 01/11/2004 |
Precedenti posizioni note di Matt Hall
| Società | Posizione | Fine |
|---|---|---|
BioCrossroads
 BioCrossroads Investment ManagersFinance BioCrossroads seeks investment opportunities in companies located in the United States. The firm targets companies operating in the fields of pharmaceutical, medical device, diagnostics, ag-biotech, health information technology and platforms sectors. It provides financing for seed and early stage capital requirements. | Investitore di Private Equity | 30/03/2022 |
NatCity Investments, Inc.
 NatCity Investments, Inc. Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | - |
Formazione di Matt Hall
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
52
Relazioni di 1° grado
8
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 8 |
|---|---|
Anika Therapeutics, Inc.
 Anika Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair | Health Technology |
NatCity Investments, Inc.
NatCity Investments, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Diagnotes, Inc.
Diagnotes, Inc. Packaged SoftwareTechnology Services Provides a communication platform for on-call healthcare services | Technology Services |
Butler University
 Butler University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Indiana University
 Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Central Indiana Corporate Partnership
The Central Indiana Corporate Partnership Miscellaneous Commercial ServicesCommercial Services Engages in focusing on human capital, entrepreneurship and innovation & business climate | Commercial Services |
BioCrossroads
BioCrossroads Investment ManagersFinance BioCrossroads seeks investment opportunities in companies located in the United States. The firm targets companies operating in the fields of pharmaceutical, medical device, diagnostics, ag-biotech, health information technology and platforms sectors. It provides financing for seed and early stage capital requirements. | Finance |
Allinaire Therapeutics LLC
Allinaire Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for cardiopulmonary diseases | Health Technology |
